Metropolitan Life Insurance Company (MetLife)’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,064
| Closed | -$20.5K | – | 2225 |
|
|
2024
Q1 | $20.5K | Sell |
3,064
-1,009
| -25% | -$6.94K | ﹤0.01% | 1853 |
|
|
2023
Q4 | $26.5K | Hold |
4,073
| – | – | ﹤0.01% | 1786 |
|
|
2023
Q3 | $38.4K | Buy |
4,073
+876
| +27% | +$10.5K | ﹤0.01% | 1550 |
|
|
2023
Q2 | $44.7K | Hold |
3,197
| – | – | ﹤0.01% | 1492 |
|
|
2023
Q1 | $60K | Sell |
3,197
-415
| -11% | -$6.82K | ﹤0.01% | 1290 |
|
|
2022
Q4 | $49.7K | Hold |
3,612
| – | – | ﹤0.01% | 1481 |
|
|
2022
Q3 | $69.1K | Sell |
3,612
-600
| -14% | -$10.9K | ﹤0.01% | 1244 |
|
|
2022
Q2 | $64.3K | Hold |
4,212
| – | – | ﹤0.01% | 1330 |
|
|
2022
Q1 | $85.8K | Sell |
4,212
-11,881
| -74% | -$242K | ﹤0.01% | 1290 |
|
|
2021
Q4 | $470K | Sell |
16,093
-1,967
| -11% | -$56.3K | 0.01% | 1478 |
|
|
2021
Q3 | $390K | Hold |
18,060
| – | – | 0.01% | 1614 |
|
|
2021
Q2 | $463K | Buy |
18,060
+1,638
| +10% | +$35K | 0.01% | 1566 |
|
|
2021
Q1 | $299K | Sell |
16,422
-1,214
| -7% | -$20.2K | ﹤0.01% | 1747 |
|
|
2020
Q4 | $204K | Buy |
17,636
+5,561
| +46% | +$50.8K | ﹤0.01% | 1923 |
|
|
2020
Q3 | $92K | Sell |
12,075
-6,450
| -35% | -$48.8K | ﹤0.01% | 2264 |
|
|
2020
Q2 | $122K | Buy |
18,525
+9,507
| +105% | +$53.1K | ﹤0.01% | 2133 |
|
|
2020
Q1 | $46.1K | Sell |
9,018
-3,696
| -29% | -$22.4K | ﹤0.01% | 2390 |
|
|
2019
Q4 | $97.5K | Sell |
12,714
-9,614
| -43% | -$56.1K | ﹤0.01% | 2348 |
|
|
2019
Q3 | $118K | Buy |
22,328
+17,459
| +359% | +$108K | ﹤0.01% | 2206 |
|
|
2019
Q2 | $27.3K | Buy |
+4,869
| New | +$20.1K | ﹤0.01% | 2565 |
|
|
2019
Q1 | – | Sell |
-18,436
| Closed | -$75.6K | – | 2575 |
|
|
2018
Q4 | $75.6K | Hold |
18,436
| – | – | ﹤0.01% | 2450 |
|
|
2018
Q3 | $126K | Buy |
+18,436
| New | +$109K | ﹤0.01% | 2314 |
|
|
2016
Q1 | – | Sell |
-21,562
| Closed | -$177K | – | 2527 |
|
|
2015
Q4 | $177K | Buy |
21,562
+3,636
| +20% | +$29.4K | ﹤0.01% | 2338 |
|
|
2015
Q3 | $128K | Buy |
17,926
+7,891
| +79% | +$65.9K | ﹤0.01% | 2536 |
|
|
2015
Q2 | $92K | Sell |
10,035
-11,236
| -53% | -$108K | ﹤0.01% | 2614 |
|
|
2015
Q1 | $201K | Sell |
21,271
-37
| -0.2% | -$356 | ﹤0.01% | 2052 |
|
|
2014
Q4 | $207K | Hold |
21,308
| – | – | ﹤0.01% | 2394 |
|
|
2014
Q3 | $203K | Buy |
21,308
+8,033
| +61% | +$89.9K | ﹤0.01% | 2354 |
|
|
2014
Q2 | $175K | Sell |
13,275
-11,304
| -46% | -$143K | ﹤0.01% | 2593 |
|
|
2014
Q1 | $327K | Hold |
24,579
| – | – | ﹤0.01% | 2098 |
|
|
2013
Q4 | $239K | Hold |
24,579
| – | – | ﹤0.01% | 2343 |
|
|
2013
Q3 | $243K | Sell |
24,579
-439
| -2% | -$4.36K | ﹤0.01% | 2276 |
|
|
2013
Q2 | $226K | Buy |
+25,018
| New | +$262K | ﹤0.01% | 2262 |
|
Other funds holding CDMO
1WCM
AC
PAIM
PCM
Metropolitan Life Insurance Company (MetLife)'s CDMO Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q2 2024, closing a stake of 3,064 shares — an estimated $20.5K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in CDMO in Q2 2013 and held it in 33 quarters. The position peaked at $470K in Q4 2021. 172 funds tracked by Wall St. Rank hold CDMO as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Avid Bioservices, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,064 Avid Bioservices, Inc. Common Stock shares in Q2 2024, an estimated $20.5K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2013 and held it in 33 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Avid Bioservices, Inc. Common Stock position peaked at $470K in Q4 2021.
- 172 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.